Introduction {#sec1-1}
============

*Acharya Charaka* has described the disease first separately by the name of '*Sandhigata Anila*' under the chapter of *Vata vyadhi*. He defined it as a disease, with the symptoms of swelling(Shotha), which is palpable as air filled bag (*Vata purna driti sparsha*) and pain on flexion and extension of the joints (*akunchana prasarane Vedana*).\[[@ref1]\] *Acharya Sushruta* described pain (*shula*), swelling (*shotha*) and diminution of the movements at the joints involved (*hanti sandhigatah*) as symptoms of *Sandhigatavata*.\[[@ref2]\] Symptoms of *Sandhigatavata* are *vatapurnadrutishopha*, and *akunchana prasarana janya Vedana* described by *Acharya Vagbhatta*.\[[@ref3]\]

In this way, the disease *Sandhigatavata* can be defined as a disease of *sandhi* (joint) with symptoms of *sandhishula*(joint pain), *sandhishotha*(swelling in joints) and *akunchana prasarana pravritti savedana*(pain during movements like flexion and extension of joints) and in the later stage *hanti sandhigatah*(restricted movements of joints). In Allopathic science, the similar condition of joint is explained as osteoarthritis. According to WHO, osteoarthritis is the second commonest musculoskeletal problem in the world population(30%) after backpain(50%).\[[@ref4]\] Osteoarthritis is the most common joint condition.\[[@ref5]\] It is a degenerative type of arthritis which mainly occurs in old age. It is a chronic degenerative disorder of multifactorial etiology characterized by loss of articular cartilage and periarticular bone remodeling.

In Allopathy science, mainly analgesics, anti inflammatory drugs or surgery are the options for the treatment of osteoarthritis. These do not give satisfactory relief and also cause great adverse effect. Researchers are looking for drugs that would prevent, slow down or reverse joint damage.

The present study is a humble effort in search of cure of the disease *Sandhigatavata*. *Acharya Charaka* has mentioned repeated use of *snehana*, *svedana*, *Vasti* and *mrudu virechana* for the treatment of *Vatavyadhi*.\[[@ref6]\] He has not mentioned the treatment of *Sandhigatavata* separately. *Acharya Sushruta* has described specific treatment for the *Sandhigatavata* first time i.e. *snehana*, *upanaha*, *agnikarma*, *bandhana* and *unmardana*.\[[@ref7]\]

*Vasti* was selected for the present study as it is shown best for the *vatavyadhies*. Here *Matra Vasti* was given with *balataila*. It has *vatashamaka* and *rasayana* properties. It is widely used in many hospitals, still no research work has been carried out with it in Gujarat Ayurved University. So for the present study, *balataila* was selected. Indigenous compound drug containing *Guggulu*, *Shallaki*, *Yastimadhu*, *Pippali*, *Guduchi, Nirgundi, Kupilu* and *Godanti* was given in one group along with *Matra Vasti*.

Aims and objectives {#sec2-1}
-------------------

To assess the effect of *Matra Vasti* with *Abhyanga- swedana* in *sandhigata Vata*To assess the effect of indigenous Ayurvedic compound drug in *Sandhigatavata*.

Materials and Methods {#sec1-2}
=====================

Patients between age group of 40 - 70 years having the below mentioned symptoms were randomly selected from O.P.D. and I.P.D. of *Kayachikitsa* department, I.P.G.T. and R.A., G.A.U., Jamnagar:

*Sandhishula* (pain in joints)*Sandhishotha* (swelling in joints)*Sandhigraha* (*Stambha*)(stiffness in joints)*Akunchana Prasaranayoh Vedana*(pain during flexion and extension of joints)*Sparsha Asahyata* (tenderness)*Sandhisphutana* (Crepitus)

Patients having the signs and symptoms of *Sandhigatavata* as described in Ayurvedic texts were selected for the clinical trial. To assess the effect of the therapy objectively, a special scoring was given to all the signs and symptoms of the disease *Sandhigatavata*.

Routine hematological, urine, stool examination, biochemical investigations like fasting blood sugar, lipid profile, serum protein, serum calcium were carried out in all the patients before and after the treatment to evaluate the status of the patient, to exclude any other pathology as well as to see the effect of therapy in these investigations, if any. X-ray examination, joint examination and walking time examination were done in all the patients before and after the treatment to assess the effect of therapy.

Criteria for assessment {#sec2-2}
-----------------------

To assess the effect of therapy objectively, all the signs and symptoms were given scoring depending upon their severity \[[Table 1](#T1){ref-type="table"}\].

###### 

Signs and symptoms scoring depending upon their severity
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Statistical analysis {#sec2-3}
--------------------

To analyze the effect of therapy statistically, mean, percentage, S.D., S.E., *t* and P values were calculated by using paired '*t*' test.

Method of administration of *Matra Vasti* {#sec2-4}
-----------------------------------------

Patients were asked to take light meal i.e- neither too *Snigdha* nor too *Ruksha* and not more than three fourth of the usual quantity. Before administration of *Vasti*, *Abhyanga* with *Balataila* was done to the whole body. Thereafter, *Bashpa Swedana* was done.

After these *Purvakarma*, the patient was advised to take left lateral position with left lower extremity straight and right lower extremity flexed on knee and hip joint. The patient was asked to keep his left hand below the head. *Balataila* was applied to anus in small amount. Sixty milliliters of luke warm *Balataila* was taken in enema syringe. Rubber catheter oleated with *Balataila* was attached to enema syringe. After removing the air from enema syringe, rubber catheter was administered into the anus of the patient upto the length of 4-5 inches. The patient was asked to take deep breath while introducing the catheter and drug. The total *taila* was not administered in order to avoid entrance of vayu into the *Pakvashaya* which may produce pain.

After the administration of *Vasti*, patient was advised to lie in supine position and patient\'s buttocks were gently tapped and legs were raised few times so as to raise the waist. After a while patient was advised to get up from the table and take rest.

### Abhyanga -Svedana {#sec3-1}

*Sarvang Abhyanga* was done approximately for 30 min with *Balataila*. After *Abhyanga*, patient was subjected to Bashpa swedana for approximately 10 min. For this, Dashamula decoction was used.

### Indigenous compound drug {#sec3-2}

The ingredients of drug were *Kupilu churna*(1 part), *Godanti Bhasma* (2 parts), *Pippali Churna* (4 part), *Yashtimadhu churna* (4 parts), *Shallaki* (10 parts), *Guggulu* (10 parts). Then 3 bhavanas of *Guduchi*, and *Nirgundi Svarasa* was given to *Yastimadha*, *Pippali* and *Kupilu churna*.

Totally, 35 patients were selected for the study. Among them 33 patients completed the treatment and 2 patients were drop outs. These patients were randomly divided into two groups as below:-

Group-A - 16 patients of this Group were treated with *sarvang Abhyanga* - *swedana* alongwith *Matra Vasti* (60 ml *balataila*) for three weeks with three days interval at every week.

Group-B - 17 patients of this Group were treated with *sarvang Abhyanga* -- *sVedana* along with *Matra Vasti* (60 ml of *balataila*) for three weeks with three days interval at every week, same as Group-A. Along with this, patients of this Group were also given indigenous compound drug in vati form 1.5 g three times daily for four weeks.

Observations {#sec1-3}
============

In the present study, majority of the patients were from the age group of 40-50 years (45.71%). Majority of the patients were females (77.14%), 62.85% patients were housewives, 68.57% patients were belonging to middle class and 88.57% patients were residing in urban area. All the patients were belonging to *anoop desha*, 77.14% patients were vegetarians, and 91.42% patients were having habit of *samashana*.

Maximum number of patients had chronicity one-two years (31.42%) followed by two-five years chronicity (25.71%), 65.71% patients were having negative family history, 80% patients were having gradual onset of the disease. In the present study, as *Nidana, ati katvadi Rasa Sevana* was present in 11.43% patients, *ati sheeta Ahara Sevana* was present in 2.86% patients, *ati Ruksha* and *ati alpa ahara sevana* were present in 2.86% patients \[[Table 3](#T3){ref-type="table"}\]. As a risk factor or causative factor \[[Table 4](#T4){ref-type="table"}\], 77.14% patients were of female sex; in 14.29% patients, family history was positive. The associated symptoms observed in this study are shown in [Table 6](#T6){ref-type="table"}.

###### 

Involvement of joints wise distribution of 35 patients of *Sandhigatavata*
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###### 

*Nidana* wise distribution of 35 patients of *Sandhigatavata*
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###### 

Risk factors wise distribution of 35 patients of *Sandhigatavata*
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###### 

Cardinal symptoms wise distribution of 35 patients of *Sandhigatavata*
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###### 

Associated symptoms wise distribution of 35 patients of *Sandhigatavata*
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In this study, all the patients (100%) were having *sandhi shula* and *sandhi sphutana*. *Akunchana prasaranayoh Vedana* and *stambha* were present in 80% patients, *sandhi shotha* was present in 71.43% patients and *sparsha-asahyata* was present in 62.86% patients \[[Table 5](#T5){ref-type="table"}\]. The involvement of joints in patients is shown in [Table 2](#T2){ref-type="table"}.

*Basti* retention time was observed as minimum of 1 hr., maximum upto 18 hrs with mean of 6 hrs.

Results {#sec1-4}
=======

Group-A: In this study, 16 patients of *Sandhigatavata* were treated with *Sarvanga Abhyanga* -- *Svedana* and *Matra Vasti* (60 ml *Bala taila*) for three weeks The effects are shown in Tables [7](#T7){ref-type="table"}--[10](#T10){ref-type="table"}.

###### 

Effect of therapy on cardinal symptoms in Group A
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###### 

Effect of therapy on associated symptoms in Group A
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###### 

Effect of therapy on walking and climbing stairs time in Group A
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###### 

Effect of therapy on joint examination in Group A
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Effect on X-ray Examination: Before treatment, mean score of arthritic changes in X-ray was 1.68, which was reduced to 1.25 after the treatment. The 25.92% relief was noted which was statistically significant (*P*\<0.05) \[[Table 11](#T11){ref-type="table"}\].

###### 

Effect of therapy on X-ray examination in Group A
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Before treatment, joint effusion was present in one patient which was absent after the treatment.

Mean score before and after treatment of all the pathological and biochemical investigations which were done for the present study was almost same. All the values were in its normal range before and after the treatment.

In 62.50% patients (10 patients), no recurrence was noted while 37.50% patients (six patients) got recurrence of symptoms in the follow up period i.e. two months after the completion of the therapy \[[Table 13](#T13){ref-type="table"}\].

###### 

Total effect of therapy in Group A
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###### 

Recurrence of symptoms (Follow up -- two months) in Group A
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Group-B: In the present study, in this group, 17 patients were treated with sarvang *Abhyanga-swedana* and *Matra Vasti* (60 ml *bala taila*) for three weeks along with indigenous compound drug was given for four weeks. The effect of therapy in group B is shown in Tables [14](#T14){ref-type="table"}--[19](#T19){ref-type="table"}.

###### 

Effect of therapy on cardinal symptoms in Group B
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###### 

Effect of therapy on associated symptoms in Group B
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###### 

Effect of therapy on walking and climbing stairs time in Group B
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###### 

Effect of therapy on joint examination in Group B
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###### 

Effect of therapy on X-ray examination in Group B
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###### 

Total effect of therapy in Group B
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Effect on X-ray Examination: The mean score of arthritic changes in X-ray was 1.64 before treatment, which was reduced to 1.28 after the treatment. Here 21.73% relief was obtained which was statistically significant (*P*\<0.05) \[[Table 18](#T18){ref-type="table"}\].

In this group, in four patients effusion was present in the joint before treatment which was absent after the treatment. Mean score before and after treatment of all the pathological and biochemical investigations which were done in the present study was almost same. All the values of the investigations were in normal range both the time.

In 52.94% patients (nine patients) no recurrence was noted while 47.05% patients (eight patients) got recurrence of symptoms in the follow up period i.e. two months after the completion of the therapy \[[Table 20](#T20){ref-type="table"}\].

###### 

Recurrence of symptoms (follow up -- two months) in Group B
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Discussion {#sec1-5}
==========

It is interesting to note that *dhatukshaya* was found in all patients. It can be understood that *sandhivata* is a geriatric problem. *Ati chinta* was found in 47.14% patients, *atishoka* found in 11.43% patients, *atikrodha* found in 8.57% patients and *atibhaya* found in 2.86% patients. These manasikanidanas cause *agnivaishamya* and *Vata prakopa*, thus leading to the production of *Sandhigatavata*.

In this series, 77.14% patients were of female sex, 48.57% patients were having psychological stress, and obesity found in 42.86% patients, repetitive stress at the joints found in 22.86% patients, history of trauma was present in 20% patients and hereditary involvement found in 14.29% patients. These factors are mentioned as risk factors for osteoarthritis in the texts and same has been found in the present study. High prevalence of female in osteoarthritis is known. Psychological stress has relation with the severity of the disease. Stress aggravates the pain and other symptoms and may also cause more joint damage. Obesity gives over burden to the joint and causes joint damage. Repetitive stress and trauma directly damages the joint. Heredity plays a role for the production of osteoarthritis especially involvement of interphalangeal joint (heberden\'s node). Prognosis is good if these risk factors are not present in the patient or if we are able to decrease these risk factors like obesity, repetitive stress etc.

The treatment modality selected for the present study aims at finding out safe, effective and cost free management of *Sandhigatavata* which can also be applied at OPD level. *Vasti* is very well known as the best treatment for *vatavyadhies*. According to *acharya charaka*, *matra vasti* is always applicable to those emaciated due to overwork, physical exercise, weight lifting, way faring, journey on vehicles and indulgence in women in debilitated person as well as in those afflicted with *Vata* disorders. The *matra vasti* is promotive of strength without any demand of strict regimen of diet, causes easy elimination of *mala* and *mutra*. It performs the function of *brimhana* and cures *vatavyadhi*.\[[@ref8]\]

Indegnious compound drug has properties like *Vedanasthapana*, *shothahara, balya, rasayan, sandhaniya, deepana, anulomana* etc. Its pharmacological activities include anti inflammatory, analgesic, anti oxidant, immunostimulant etc. By these properties, this drug is beneficial for the shamana of *Sandhigatavata*.

Considering the above aspects, the present study was undertaken and the results supported the hypothesis of the study which are as follows-

Comparative effect of therapies on cardinal symptoms {#sec2-5}
----------------------------------------------------

In Group-A and Group-B, highly significant relief (*P* \< 0.001) was found in *sandhishula* with relief of 64.15% and 59.61% respectively. In Group-A, percentage relief is higher than Group-B where only *matra vasti* was given \[Tables [7](#T7){ref-type="table"} & [14](#T14){ref-type="table"}\].

In Group-A and Group-B, highly significant relief was found (*P* \< 0.001) in the symptom *sandhishotha* with the relief of 66.66% in both the groups. So the percentage of relief was same in both the groups.

In Group-A , highly significant relief (*P* \< 0. 001) was found in *akunchana prasaranayoh Vedana* while in Group-B, the relief was significant (*P* \< 0.05). In Group-A, 80% relief was achieved while in Group-B, percentage relief was 57.89%. Here, in the symptom of akunchana prasaranayoh *Vedana*, in Group-A higher percentage relief was found than Group-B.

In Group-A and Group-B, highly significant result was found (*P* \< 0.001) in the symptom *Sandhi Sphutana* in both the groups with percentage relief 66.66% and 32.25%, respectively. Though highly significant result found in both the groups, percentage relief was greater in Group-A.

In Group-A, highly significant relief (*P* \< 0.001) was found in *Sparsha Asahyata*. Also in Group-B, highly significant relief was found at the level of *P* \< 0.01. Percentage relief of 73.68% and 57.14% was noted respectively. Here also percentage relief was higher in Group-A.

In Group-A and Group-B, highly significant relief (*P* \<0.001) was found in the symptom *Stambha* with percentage relief 71.87% and 65.62%, respectively. Percentage relief was greater in Group-A.

Effect of therapies on walking and climbing stairs time {#sec2-6}
-------------------------------------------------------

Highly significant result was found in both Groups. In Group-A, percentage relief in walking time was 20.70% and in climbing stairs time was 16.28% \[[Table 9](#T9){ref-type="table"}\]. In Group-B, percentage relief in walking time was 22.79% and in climbing stairs was 18.15% \[[Table 16](#T16){ref-type="table"}\]. In walking time and climbing stairs time, slightly greater relief was found in Group-B in comparison to Group-A. This could be due to the indigenous compound drug.

Effect of therapies on joint examination {#sec2-7}
----------------------------------------

In Group-A, relief in knee joint flexion was highly significant. Relief found in hip joint flexion was insignificant. Relief found in S.L.R. (right leg) was significant while S.L.R. (left leg) was insignificant. Percentage relief obtained was knee joint flexion Lf. (5.18%) Rt. (4.66%), hip joint flexion Lt. (0.91%), Rt. (8.38%), S.L.R. Lt (8.04), Rt(10.5%) \[[Table 10](#T10){ref-type="table"}\].

In Group-B, relief in knee joint flexion was highly significant. Improvement in S.L.R. was significant. Improvement in hip joint flexion (right leg) was significant and it was insignificant to left hip joint. Percentage relief found was knee joint flexion Lf. (4.28%). Rt. (6.86%), hip joint flexion Lf. (3.13%), Rt. (4.07%) S.L.R. Lf. (8.57%), Rt. (10.21%) \[[Table 17](#T17){ref-type="table"}\].

Percentage relief of knee joint flexion left in Group-A was 5.18% and in Group-B was 4.28%. Here better relief was in Group-A. On Rt. knee joint, percentage relief was 4.66% in Group-A and 6.86% in Group-B. Here more relief was in Group-B.

Percentage relief of hip joint flexion left in Group-A was 0.91% and in Group-B was 3.13%. Here higher relief was in Group-B. On right hip joint, percentage relief was 8.38% in Group-A and 4.07% in Group-B. Here more relief was obtained in Group-A.

Percentage relief in S.L.R. left in Group-A was 8.04% and in Group-B was 8.57%. Almost same relief was found in both the Groups. On right side, percentage relief was 10.50% in Group-A and 10.21% in Group-B. Same relief was found in both the groups.

Effect of therapies on X-ray examination {#sec2-8}
----------------------------------------

In both the groups, significant relief was found (*P* \< 0.05). Percentage relief in Group-A was 25.92% \[[Table 11](#T11){ref-type="table"}\] and in Group-B, it was 21.73% \[[Table 18](#T18){ref-type="table"}\]. Slightly greater relief was found in Group-A in comparison to Group-B in X-ray examination.

Effect of therapies on joint effusion (X-ray examination) {#sec2-9}
---------------------------------------------------------

In Group-A, in one patient, knee joint effusion was present in X-ray examination before treatment and it was absent after treatment. In Group-B, in four patients, knee joint effusion was present before treatment. Among them, in three patients, it was absent after treatment in X-ray examination. Here, both the groups obtained good result in joint effusion.

Though joint effusion is not a characteristic feature of osteoarthritis, the pathological condition in knee joint associated with oseteoarthirtis can also be treated successfully by this modality.

Probable mode of action {#sec2-10}
-----------------------

*Vasti - Vasti* is the best treatment for *Vata* as said by *Acharya Charaka* "*Vastihi Vataharanam*". *Vasti* drug first reaches to the *Pakvashaya*(large intestine). *Pakvashaya* is the chief site of *Vatadosha*. Thus, by its action on the chief site, *Vasti* gets control on *Vata* all over the body. *Pakvashaya* is the site of *Purishadharakala*. Commentator *Dalhana* has said *Purishadhara* and *Asthidhara kala* are one and same.\[[@ref9]\] *Vasti* drugs directly acts on *Purishadharakala* so we can take its direct action on *Asthidharakala* also. *Sushruta* has mentioned 6^th^ *Vasti* nourishes *Mamsa Dhatu*, 7^th^ *Vasti* nourishes *Meda Dhatu*, 8^th^ *Vasti* nourishes *Asthi Dhatu* and 9^th^ *Vasti* nourishes *Majja Dhatu*.\[[@ref10]\] Thus, through *Vasti*, we achieve *Vata Dosha Shamana* and *Snehana* of *Asthi Dhatu*. So we achieve the *Shamana* of *Sandhigatavata* by breaking the *Samprapti*. According to modern medical science, as per *Vasti* /*Enema* concerned, in trans rectal route, the rectum has a rich blood and lymph supply and drug can cross the rectal mucosa like other lipid membrane. Thus by entering in general circulation, *Vasti* drugs acts on whole the body.

*Vasti* may act through the nervous system or through the enteric receptors. It may increase the secretion of local enzyme or neurotransmitters. *Vasti* influences the normal bacterial flora, thus it increases the endogenous synthesis of vitamin B~12,~ vitamin K etc.

*Bala* used in *matravasti* gives "Bala" to the body. It has *Vatasansaman* and *Rasayana* properties. So it is very good in *Vatavyadhies* i.e. degenerative disorders. Its pharmacological activities include rejuvinative, anti inflammatory, analgesic etc. *Balataila* is good in all types of *Vatavyadhi*, *Raktapitta*, *Yoniroga*, *Talushosha*,etc.\[[@ref11]\]

In osteoarthritis, there is disruption of glue which binds the cells of the cartilage, so cartilage damage takes place. *Taila* by its qualities like *tikshna*, *suksma* penetrate the cartilage and by its *Snigdha*, *Guru* qualities provides glue which binds the cartilage cells. This action of taila is considered as "*sandhaniya*".

*Abhyanga*(massage) - *Abhyanga* directly acts on muscles and makes them strong. The root of *Mamsavaha* *Srotas* is *Snayu*(ligaments), *Tvacha*(skin) and *Raktavahini*(blood vessels). So here, *Abhyanga* is done over *Tvacha* and *Snayu* and also it involves *Raktavahini*. So here, direct benefit is achieved at *Mamsavaha Srotas*. *Abhyanga* nourishes deeper *Dhatus* also. Here, one thing we can say that *Abhyanga* makes the muscles strong and thus get the stable joint.

*Swedana*(fomentation): *Swedana* is *Sandhichestakar* (improvises the movements of joints), *Srotoshuddhikar* (clears up the micro channels), *Agni Deepaka*, *Kaphavatanirodhan*(antagonist of *Kapha*). It decreases *Sthambha*(stiffness). Heat administration by *Swedana* may produce hypno analgesic effect by diverted stimuli. In *Sandhigatavata*, *Sanga* type of *Srotodushti* is present *Swedana*, by doing *Srotoshuddhi*, this Sanga is releaved.

Indigenous compound drug: It has properties like *Vedanasthapana* (analgesic), *shothahara* (anti-inflammatory), *balya*, *rasayan*, *sandhaniya, deepana, anulomana* etc. Its pharmacological activities include anti inflammatory, analgesic, anti oxidant, immunostimulant etc. By these properties, this drug is beneficial for the *shamana* of *Sandhigatavata*.

Conclusion {#sec1-6}
==========

Complete remission was found in 43.75% patients in Group-A \[[Table 12](#T12){ref-type="table"}\] and 23.52% patients in Group-B \[[Table 19](#T19){ref-type="table"}\]. Marked improvement was found in 37.50% patient in Group-A while 47.05% in Group-B. Moderate improvement was found in 18.75% patients in Group-A and 29.41% patients in Group-B. In Group-A, more number of patients got complete remission in comparison to Group-B. Otherwise, almost equal result is obtained in both the groups.

With these results, it can be said that sarvang *Abhyanga-swedana* and *Matra Vasti* serve all the needs which are required for the *shamana* of *Sandhigatavata*. Along with present therapy, addition of *sthaulyahara* treatment in *sthula* patients and long duration of therapy may provide better relief. Addition of exercise may help in improving joint function.
